Clinical trials: Myasthenia Gravis
Generalized Myasthenia Gravis
Safety and Efficacy Study of RA101495 in Subjects With Generalized Myasthenia Gravis
The purpose of the study is to evaluate the safety and efficacy of RA101495 in patients with generalized Myasthenia Gravis (gMG).
- Trial name
- NCT03315130
- Testing
- zilucoplan (RA101495)
- Where
- 30 sites in United States, Canada
- Volunteers
- 45 people
- Sponsor
- Ra Pharmaceuticals
Myasthenia Gravis
The Impact of Myasthenia Gravis in the Real World
An international, non-interventional, prospective, community recruited, longitudinal, lifestyle study which aims to collect Real-World Evidence (RWE) from people living with myasthenia gravis (MG) in order to map the disease's…
- Trial name
- NCT04176211
- Where
- United Kingdom
- Volunteers
- 2,847 people
- Sponsor
- Vitaccess Ltd
Myasthenia Gravis
Trial of Mycophenolic Acid Versus Azathioprine in the Treatment of Corticosteroid-refractory Myasthenia Gravis
This is an randomized, double-blind, double-dummy trial, and the objective is to compare the efficacy and safety of Mycophenolic acid (MA) and Azathioprine (AZA), immunosuppressive drugs, in myasthenia gravis patients.
- Trial name
- Myfortic (NCT00997412)
- Testing
- Mycophenolic acid, AZA
- Volunteers
- 40 people
- Sponsor
- Qualitix Clinical Research Co., Ltd.
Myasthenia Gravis
Perioperative Efgartigimod for Thymoma and Myasthenia Gravis
It is evidenced that efgartigimod can rapidly and significantly improve the symptoms of myasthenia gravis. The global multicenter clinical trials hace confirmed that efgartigimod is safe and well tolerated.
- Trial name
- NCT06221501
- Testing
- Efgartigimod Alfa
- Volunteers
- 30 people
- Sponsor
- Shanghai Zhongshan Hospital
Myasthenia Gravis, Thymoma
The Role of the Thymus in Myasthenia Gravis
Although the association between thymic hyperplasia / thymoma and autoimmune myasthenia gravis has been known for some time, the question of causality remains uncertain.
- Trial name
- NCT01102192
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- Charite University, Berlin, Germany
Myasthenia Gravis, Generalized
Markers of Favorable Response to Complement Inhibitors Therapy
Myasthenia gravis is an autoimmune neurological disease caused by autoantibodies primarily directed against components of the postsynaptic membrane of the neuromuscular junction.
- Trial name
- OPTIMISE (NCT06455709)
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Myasthenia Gravis
Phase 4 Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Chinese Participants With Generalized Myasthenia Gravis
The purpose of the study is to assess the clinical efficacy of rozanolixizumab in adult Chinese participants with generalized myasthenia gravis (gMG) in the first Treatment Cycle.
- Trial name
- NCT07246564
- Testing
- Rozanolixizumab
- Where
- 12 sites in China
- Volunteers
- 40 people
- Sponsor
- UCB Biopharma SRL
Refractory Myasthenia Gravis
Efficacy and Safety of HN2301 in Refractory Myasthenia Gravis(MG)
This is an investigator-initiated trial designed to evaluate the safety, and efficacy of HN2301 in refractory myasthenia gravis
- Trial name
- NCT06965309
- Testing
- HN2301 injection
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Shenzhen MagicRNA Biotechnology Co., Ltd
Acute Inflammatory Demyelinating Polyradiculoneuropathy, Myasthenia Gravis
Perception and Multisensory Integration in Neurological Patients Using fMRI
The main objective of the study is to explore and map brain areas involved in sensory perception and multisensory integration in patients with central or peripheral neurological damage.
- Conditions
- Acute Inflammatory Demyelinating Polyradiculoneuropathy, Myasthenia Gravis, Stroke, Anosognosia
- Trial name
- NCT01469858
- Testing
- Siemens magnetom avanto1.5 Tesla, Siemens magnetom trio A Tim system 3 Tesla
- Where
- Israel
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Hadassah Medical Organization
Generalized Myasthenia Gravis (gMG)
GC012F Injection in the Treatment of Refractory Generalized Myasthenia Gravis(24103)
This is a single-arm, open-label and early exploratory clinical study, with the purpose to study the safety, tolerability and initial clinical efficacy of GC012F Injection in the treatment of refractory GMG and to evaluate the…
- Trial name
- NCT07058298
- Testing
- GC012F injection
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Daishi Tian
Myasthenia Gravis
Cognitive Functioning in People With Myasthenia Graivs: Impact on Daily Life Activities, Work, Disability and Quality of Life
MYCOG primarily aims to estimate the prevalence of cognitive difficulties in patients with MG treated at Besta Institute. Secondary aims include: a) assess the degree to which cognitive difficulties are associated to work…
- Trial name
- MYCOG (NCT06718855)
- Where
- Italy
- Volunteers
- 150 people
- Sponsor
- Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Myasthenia Gravis
Influences of Sugammadex on Postoperative Progress in Patients With Myasthenia Gravis Undergoing Video-assisted Thoracoscopic Thymectomy: Retrospective Study
"Several case reports have described the use of rocuronium and sugammadex in patients with myasthenia gravis (MG). However, reports regarding the effects of sugammadex compared with that of acetylcholinesterase inhibitors…
- Trial name
- NCT05694234
- Where
- South Korea
- Volunteers
- 265 people
- Sponsor
- Yonsei University
Myasthenia Gravis
A Study to Evaluate the Safety and Preliminary Efficacy of SYS6020 CAR T-cells in Patients With Refractory Generalized Myasthenia Gravis
This study is a single-arm, open, 2-stage (dose-escalation phase and dose-expansion phase), multi-center, phase I clinical trial to evaluate the safety and tolerance of SYS6020 injection in the participants with refractory…
- Trial name
- NCT06688435
- Testing
- SYS6020 injection
- Where
- China
- Volunteers
- 60 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Myasthenia Gravis
Precision Diagnosis and Prospective Cohort Study for Myasthenia Gravis: Multicenter Analysis in China
The present study is a prospective cohort study aiming to improve the clinical capacity in the diagnosis and natural history of Chinese patients with myasthenia gravis (MG).
- Trial name
- NCT04535843
- Testing
- Biomarkers and omics data
- Where
- 4 sites in China
- Volunteers
- 500 people
- Sponsor
- Huashan Hospital
Guillain-Barre Syndrome, Myasthenia Gravis
Diaphragm Thickness by Ultrasonography in Neurological Disorders
participants will be allocated into three groups, acute neuropathy (Guillain Barre Syndrome) group, neuromuscular junction disorder(myasthenia gravis ) group, and control group(people with neurological disorders not affecting the…
- Trial name
- NCT05324176
- Testing
- diaphragmatic ultrasound
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Mansoura University
Generalized Myasthenia Gravis
A Safety and Tolerability Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness.
This is a Long-Term, Single-Arm, Open-Label, Multicenter Phase 3 follow-on trial of the ARGX-113-1704 study to evaluate the safety and tolerability of ARGX-113 in patients with gMG.
- Trial name
- ADAPT+ (NCT03770403)
- Testing
- ARGX-113
- Where
- 52 sites in United States, Belgium and 13 more
- Volunteers
- 151 people
- Sponsor
- argenx
Myasthenia Gravis, Fatigue
Capturing Key MG-symptoms Using Smartphone Recordings.
This study will make use of a cross-sectional design of MG patients and non-MG participants to quantitatively assess key MG symptoms, and to explore the applicability of machine learning algorithms to their measurement.
- Trial name
- CAPTURE - MG (NCT06743490)
- Where
- 2 sites in Netherlands
- Volunteers
- 225 people, healthy volunteers welcome
- Sponsor
- Leiden University Medical Center
Myasthenia Gravis
Light vs. Moderate Intensity Exercise in Individuals With Myasthenia Gravis
The overall purpose of this pilot study is to examine the feasibility, acceptability, and tolerability of light and moderate intensity exercise in adults with MGeffect of light vs. moderate intensity exercise on health outcomes.
- Trial name
- MG-Ex (NCT06491238)
- Testing
- Light Intensity Exercise, Moderate Intensity Exercise
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- HealthPartners Institute
Myasthenia Gravis
A Pilot Study of Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Generalized Myasthenia Gravis
The purpose of this study is to determine whether the drug Leukine (GM-CFS) is safe and tolerated by patients with autoimmune myasthenia gravis (MG).
- Trial name
- NCT01555580
- Testing
- Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Muscular Dystrophy Association
Generalized Myasthenia Gravis, Myasthenia Gravis
Study of ALXN2050 in Adult Participants With Generalized Myasthenia Gravis
This study will evaluate the efficacy and safety of ALXN2050 (120 milligrams [mg], 180 mg) in participants with generalized myasthenia gravis (gMG). Safety will be monitored throughout the study.
- Trial name
- NCT05218096
- Testing
- ALXN2050
- Where
- 46 sites in United States, Canada and 6 more
- Volunteers
- 70 people
- Sponsor
- Alexion Pharmaceuticals, Inc.